Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development UpdatesGlobeNewsWire • 05/10/22
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated TrialGlobeNewsWire • 05/05/22
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022GlobeNewsWire • 04/26/22
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHDGlobeNewsWire • 04/11/22
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/11/22
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH TrialsGlobeNewsWire • 03/10/22
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022GlobeNewsWire • 02/23/22
Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a TurnaroundZacks Investment Research • 11/24/21
Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should KnowZacks Investment Research • 11/08/21
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical UpdatesGlobeNewsWire • 11/03/21
Lumos Pharma to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021GlobeNewsWire • 10/21/21
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/05/21
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate UpdatesGlobeNewsWire • 08/05/21
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory BoardGlobeNewsWire • 07/26/21
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021GlobeNewsWire • 07/22/21
Lumos Pharma Delays Data Readout From Pediatric Growth Hormone Deficiency Trial To 2H Of 2023Benzinga • 07/21/21
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for EnrollmentGlobeNewsWire • 06/28/21
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate UpdatesGlobeNewsWire • 05/05/21
Lumos Pharma to Report First Quarter 2021 Financial Results and Host Conference Call on May 5, 2021GlobeNewsWire • 04/28/21
Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned SuccessionGlobeNewsWire • 04/20/21